Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 25, 2026

Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

Chimeric AAV Cap sequences alter gene transduction.

Peter Ward1, Christopher E Walsh

  • 1Mount Sinai School of Medicine, One Gustave Levy Place, Box 1079, New York, NY 10029, USA.

Virology
|February 24, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pollution to prevention: digital decision support for air pollution and exercise counselling in general practice.

The British journal of general practice : the journal of the Royal College of General Practitioners·2026
Same author

Weight-Bearing Status After Peri-Prosthetic Proximal Femur Fracture Open Reduction and Internal Fixation (ORIF) or Revision Arthroplasty: A Clinical Audit.

Cureus·2025
Same author

How safe is kitesurfing? A review of orthopaedic kitesurfing injuries.

Irish journal of medical science·2025
Same author

Cities, communities and clinics can be testbeds for human exposome and aging research.

Nature medicine·2025
Same author

Artificial intelligence-based digital pathology for the detection and quantification of soil-transmitted helminths eggs.

PLoS neglected tropical diseases·2024
Same author

If we're serious about dental access...

British dental journal·2024
Same journal

ASFV pDP238L negatively regulates type I interferon production via inhibiting the methylation of TBK1.

Virology·2026
Same journal

Divergent poxvirus identified in a non-native black rat from Madagascar.

Virology·2026
Same journal

Genomic and functional characterization of Bacillus phage BCE1 targeting a key gut bacterium in Aedes albopictus larvae.

Virology·2026
Same journal

Viral etiology of orogenital papillomatosis and squamous cell carcinoma in bottlenose dolphins in the southeastern United States.

Virology·2026
Same journal

Orthoflaviviruses in the modern era: Challenges and breakthroughs.

Virology·2026
Same journal

Post-COVID-19 immune dysregulation and autoimmune sequelae.

Virology·2026
See all related articles

Engineered adeno-associated virus (AAV) capsids were selected for improved gene delivery. However, the resulting virus showed limited applicability, demonstrating selection specificity rather than broad utility.

Area of Science:

  • Molecular Biology
  • Virology
  • Biotechnology

Background:

  • Recombinant adeno-associated viruses (rAAV) are critical gene delivery vectors, with diverse serotypes exhibiting varying transduction efficiencies.
  • Differences in rAAV serotype capsid structures are largely responsible for their distinct gene delivery capabilities.
  • Current rAAV serotypes demonstrate suboptimal transduction efficiency in cell lines and in vivo, necessitating the development of improved vectors.

Purpose of the Study:

  • To investigate whether natural or laboratory-based selection can yield rAAVs with sharply defined optimal specificity.
  • To engineer and select a novel rAAV capsid with enhanced transduction capabilities for Hep G2 cells.
  • To evaluate the broader applicability of the selected rAAV capsid beyond its specific selection target.

Main Methods:

More Related Videos

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 25, 2026

Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
21:55

Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling

Published on: April 2, 2012

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

  • Randomly recombined capsid variants were generated using STEP and shuffling techniques with known AAV serotype sequences.
  • Selection methods were employed to identify rAAV capsids with superior transduction efficiency in Hep G2 cells.
  • The selected rAAV capsid was further tested in various cell types to assess its target specificity and applicability.

Main Results:

  • A novel rAAV capsid was successfully selected for enhanced transduction of Hep G2 cells.
  • The selected rAAV capsid demonstrated significantly improved performance in Hep G2 cells compared to existing serotypes.
  • In subsequent tests, the selected capsid exhibited surprisingly limited transduction efficiency in other cell types, indicating narrow specificity.

Conclusions:

  • Laboratory-based selection can generate rAAV capsids with enhanced specificity for particular cell types.
  • The selection process resulted in a virus tailored to the specific selection methodology and target cell.
  • The findings suggest that achieving broad applicability in engineered rAAV vectors remains a challenge.